Matrine

Matrine is a quinolizidine alkaloid derived from Sophora flavescens that exhibits hepatoprotective and anti-inflammatory properties. It works primarily by modulating NF-κB signaling pathways and reducing inflammatory cytokine production.

Category: Compound Evidence: 6/10 Tier: Preliminary (in-vitro/animal)

Origin & History

Matrine is a tetracyclic quinolizidine alkaloid extracted primarily from the roots of Sophora flavescens (Ku Shen) and Sophora alopecuroides, plants used in traditional Chinese medicine. It is isolated through alkaloid fractionation methods such as solvent extraction and chromatography, yielding matrine as a key bioactive compound alongside related alkaloids.

Historical & Cultural Context

Matrine originates from traditional Chinese medicine (TCM), where Sophora flavescens roots have been used for centuries to treat inflammation, pain, infections, and respiratory issues. Historical TCM applications included treating inflammatory edema (similar to aspirin effects), diabetic complications, and arrhythmias, with modern research building upon these traditional uses.

Health Benefits

• May support liver health: Animal meta-analysis (n=657 experiments) showed significant reductions in liver injury markers including AST (SMD = -3.76, p<0.0001) - preliminary evidence only
• Potential anti-cancer properties: Preclinical studies demonstrate apoptosis induction in colorectal cancer cells via Bcl-2/caspase-3 pathways (PMID: 30466620) - in vitro evidence only
• Anti-inflammatory effects: Animal studies show downregulation of inflammatory markers TNF-α, IL-6, COX-2, and iNOS - preliminary evidence
• May help with perianal infections: One RCT reported effectiveness of matrine sitz bath for post-chemotherapy infections in acute leukemia patients (PMID: 32498526) - limited human evidence
• Potential cardiovascular support: Preclinical data suggests calcium regulation in cardiomyocytes and β3-AR inhibition - animal evidence only

How It Works

Matrine inhibits nuclear factor kappa B (NF-κB) translocation, reducing production of inflammatory mediators like TNF-α and IL-6. The compound also modulates mitochondrial apoptotic pathways by regulating Bcl-2 family proteins and cytochrome c release. Additionally, matrine influences hepatic stellate cell activation and collagen synthesis through TGF-β1 pathway modulation.

Scientific Research

Human clinical evidence for matrine is limited, with one RCT examining matrine sitz bath for perianal infection in acute leukemia patients (PMID: 32498526), though specific outcomes were not detailed. A systematic review and meta-analysis of animal studies (n=657 experiments) demonstrated significant liver protective effects at 20-30 mg/kg/day in rats, with AST reductions (SMD = -3.76, 95% CI [-4.74, -2.78], p<0.0001). Most evidence remains preclinical, including anticancer effects demonstrated in colorectal cancer cells (PMID: 30466620).

Clinical Summary

Current evidence comes primarily from animal studies, with a meta-analysis of 657 experiments showing significant reductions in liver injury markers (AST reduction SMD = -3.76, p<0.0001). Preclinical research demonstrates anti-cancer effects through apoptosis induction in colorectal cancer cell lines. Human clinical trials are limited, making safety and efficacy data preliminary. Most research focuses on hepatoprotective effects against chemical-induced liver damage in rodent models.

Nutritional Profile

Matrine is a pure alkaloid compound (C15H24N2O, molecular weight 248.36 g/mol) extracted primarily from Sophora flavescens (Ku Shen) and related Sophora species. It is not a food ingredient and therefore contains no macronutrients (protein, carbohydrates, fats), dietary fiber, vitamins, or minerals in any meaningful sense. As a bioactive compound, it is the primary active constituent of interest. Typical standardized extracts of Sophora flavescens root contain 0.5–2% matrine by dry weight, with oxymatrine (its N-oxide metabolite) co-occurring at comparable concentrations. Pharmaceutical-grade isolated matrine is available at >98% purity. Bioavailability: Oral bioavailability in animal models is approximately 30–50%, with peak plasma concentration (Tmax) reached within 1–2 hours post-administration. It undergoes hepatic metabolism, with oxymatrine serving as both a co-occurring natural analog and a primary metabolite. Matrine crosses the blood-brain barrier to a limited degree. Half-life is approximately 2–4 hours in rodent models; human pharmacokinetic data are limited. No caloric value; no fiber, vitamin, or mineral content applicable.

Preparation & Dosage

Animal studies suggest optimal dosing at 10-69.1 mg/kg with 20-30 mg/kg/day showing high protection and low toxicity in rats over 0.02-0.86 weeks. Human dosage recommendations are not established due to limited clinical trials. Toxicity may increase above 69.1 mg/kg or with use beyond 4 weeks based on animal data. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Milk thistle, curcumin, quercetin, NAC, alpha-lipoic acid

Safety & Interactions

Matrine may cause gastrointestinal upset, dizziness, and skin reactions in some individuals. The compound can potentially interact with hepatically metabolized drugs due to its effects on liver enzymes. Pregnant and breastfeeding women should avoid matrine due to insufficient safety data. High doses may cause cardiac arrhythmias and should be avoided in individuals with heart conditions.